CRYOPORT, INC. Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost
CRYOPORT, INC. (CYRX) had Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost of $3.85 million as of 2025-12-31, per its 10-K filed 2026-03-05.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Deferred Tax Assets, Net › Deferred Tax Assets, Net of Valuation Allowance › Deferred Tax Assets, Gross › Deferred Tax Assets, Tax Deferred Expense
us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost · last filed 2026-03-05
- 2025-12-31: Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost $3.85M.
- 2024-12-31: Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost $5.39M; Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost as first filed $5.55M.
- 2023-12-31: Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost $5.65M.
- 2022-12-31: Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost $4.85M.
| Period end | Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost | Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost as first filed |
|---|---|---|
| 2025-12-31 | $3.85M 10-K · filed 2026-03-05 | |
| 2024-12-31 | $5.39M 10-K · filed 2026-03-05 | $5.55M 10-K · filed 2025-03-07 |
| 2023-12-31 | $5.65M 10-K · filed 2025-03-07 | |
| 2022-12-31 | $4.85M 10-K · filed 2024-03-13 | |
| 2021-12-31 | $4.15M 10-K · filed 2023-02-28 | |
| 2020-12-31 | $4.12M 10-K · filed 2022-02-28 | |
| 2019-12-31 | $3.82M 10-K · filed 2021-03-01 | |
| 2018-12-31 | $2.57M 10-K · filed 2020-03-10 | |
| 2017-12-31 | $2.01M 10-K · filed 2019-03-13 | |
| 2016-12-31 | $2.32M 10-K · filed 2018-03-08 | |
| 2016-03-31 | $2.12M 10-KT · filed 2017-03-13 | |
| 2015-03-31 | $1.55M 10-K · filed 2016-06-28 | |
| 2014-03-31 | $1.65M 10-K · filed 2015-05-19 | |
| 2013-03-31 | $1.32M 10-K · filed 2014-06-25 | |
| 2012-03-31 | $1.05M 10-K · filed 2013-06-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 | |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |